A pioneering study by sleep researchers at Stanford University, in collaboration with SoundHealth Inc., explores how smartphone facial scans powered by artificial intelligence can analyze facial structures linked to sleep disorders. This innovative approach uses smartphone cameras to assess craniofacial and maxillofacial features, shedding light on potential anatomical contributors to […]
Tag: obstructive sleep apnea (osa)
LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints
LivaNova PLC, a market-leading medical technology company, announced that it met the primary endpoints for its OSPREY randomized controlled trial (RCT), Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation. Together with its safety endpoints, the RCT achieved statistical significance of its primary endpoint responder rates1,2 between the treatment arm […]
Rio II Full Face Mask from React Health
React Health has announced the latest addition to its Rio II family of masks: the Rio II Full Face Mask, which is now available. Designed to enhance patient comfort and compliance with sleep therapy, the Rio II offers a cost-competitive alternative to many leading masks on the market without compromising […]
Ognomy Inc. Raises $6.8 Million to Lead the Future of Sleep Apnea Care
Ognomy Inc., a trailblazing telemedicine platform dedicated to transforming sleep apnea care, proudly announces the successful completion of its Series Seed Preferred financing round, bringing its total funding to over $6.8 million. This funding milestone coincides with the company surpassing 11,000 patients served, marking a pivotal moment in its mission […]
EnsoData, Nonin Partner to Offer Affordable Home Sleep Apnea Testing
EnsoData and Nonin partner to address the underserved and undiagnosed sleep apnea patient population with a collaborative home sleep apnea testing approach. The partnership will combine the recently FDA-cleared EnsoSleep PPG software as a medical device (SaMD) algorithm with Nonin’s WristOx2® Model 3150 reusable wrist-worn device, offering sleep labs an […]
How Orofacial Myofunctional Therapy Can Aid in the Treatment of Sleep-Disordered Breathing
There has been an increasing number of studies looking at orofacial myofunctional therapy (OMT) as a promising adjunctive treatment for obstructive sleep apnea (OSA).1 OMT essentially helps the patient to retrain the muscles around the face, mouth, and tongue to establish correct oral rest posture and functioning of the oral […]
Cannabinoid-Based Sleep Apnea Treatment Begins Dosing in Phase 2/3 Trial
Incannex Healthcare Inc., a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies, is pleased to announce that patient dosing has commenced in the Company’s Phase 2/3 clinical trial to assess the safety and efficacy of IHL-42X in patients with obstructive sleep apnea (OSA). IHL-42X is the Company’s […]
React Health Launches IntelliPAP™ Auto-Adjusting PEEP for OSA in Most V Series Ventilators
IntelliPAP™ is a new optional tool for physicians to use in noninvasive ventilation for patients with respiratory insufficiency and obstructive sleep apnea (OSA). This innovative device automatically adjusts the positive end-expiratory pressure (PEEP) levels in response to sleep-disordered breathing (SDB) events. To enhance safety, clinicians can set minimum and maximum […]
Panthera to Present Abstracts and Launch Inaugural “Panthera Sleep Research Grant” at AADSM & SLEEP 2024
Panthera Dental proudly announces that two distinct abstracts were accepted for poster presentations at the AADSM and AASM/SLEEP Annual Meetings. In addition, a funding opportunity through Panthera for investigator-initiated research proposals will be announced. The posters and the “Panthera Sleep Research Grant” reflect Panthera’s dedication to advancing dental sleep medicine […]
Nyxoah DREAM U.S. Pivotal Study Meets Primary Endpoints
Nyxoah SA has announced the DREAM U.S. pivotal study achieved a statistically significant reduction in the co-primary endpoints of 12-month AHI responder rate, per the Sher criteria, and ODI responder rate, both on an ITT basis. The DREAM study is a pivotal trial being conducted under an investigational device exemption […]













